Earnings Summary

Global Blood Therapeutics, Inc.’s revenue jumped 41.28% since last year same period to $55.16Mn in the Q1 2022. On a quarterly growth basis, Global Blood Therapeutics, Inc. has generated -1.67% fall in its revenue since last 3-months.

Global Blood Therapeutics, Inc.’s net profit fell -8.67% since last year same period to $-81.42Mn in the Q1 2022. On a quarterly growth basis, Global Blood Therapeutics, Inc. has generated 7.03% jump in its net profits since last 3-months.

Global Blood Therapeutics, Inc.’s net profit margin jumped 23.09% since last year same period to -147.61% in the Q1 2022. On a quarterly growth basis, Global Blood Therapeutics, Inc. has generated 5.45% jump in its net profit margins since last 3-months.

Global Blood Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.18 - a 9.23% jump from last quarter’s estimates.

Global Blood Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -1.18.

Global Blood Therapeutics, Inc.’s earning per share (EPS) fell -4.13% since last year same period to -1.26 in the Q1 2022. This indicates that the Global Blood Therapeutics, Inc. has generated -4.13% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Global Blood Therapeutics, Inc.’s return on assets (ROA) stands at -0.25.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Global Blood Therapeutics, Inc.’s return on equity (ROE) stands at -1.49.